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Objective. To review the contribution of vesicoureteral reﬂux and reﬂux nephropathy to end-stage renal disease. Data Source.
Publishedresearcharticlesandpubliclyavailableregistries.Results.Vesicoureteralreﬂux(VUR)iscommonlyidentiﬁedinpediatric
patients and can be associated with reﬂux nephropathy (RN), chronic kidney disease (CKD), and rarely end-stage renal disease
(ESRD). Patients with reduced GFR, bilateral disease, grade V VUR, proteinuria, and hypertension are more likely to progress
to CKD and ESRD. Because progression to ESRD is rare in VUR and often requires many decades to develop, there are limited
prospective, randomized, controlled trials available to direct therapy to prevent progression to ESRD. Conclusions. Identiﬁcation
of patients with increased risk of progression to CKD and ESRD should be the goal of clinical, biochemical, and radiological
evaluationofpatientswithVUR.TreatmentofpatientswithVURshouldbedirectedatpreventingnewrenalinjuryandpreserving
renal function.
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1. INTRODUCTION
Vesicoureteralreﬂux(VUR)isacommonﬁndinginpediatric
patients. Approximately 1/3 of patients who have had a
urinary tract infection (UTI) have VUR and 9–20% of
patientswithprenatalhydronephrosishaveVURwhentested
postnatally [1]. The prevalence of VUR in the general
pediatric population has been estimated recently to be as
high as 17.2% [1, 2]. Some patients with VUR develop reﬂux
nephropathy (RN), some patients with RN develop chronic
kidney disease (CKD), and a small number of patients
progress to end-stage renal disease (ESRD). While UTI and
VUR are relatively common, ESRD is rare in the pediatric
population with an unadjusted incident rate of 14.8 per
million patients per year in 2005 for ages 0–18 years [3]. The
goal of this article is to describe the contribution of VUR
to ESRD in pediatric patients, deﬁne risks for progression,
and review data indicating what treatments may prevent
progression to ESRD for patients with VUR.
2. RENAL PATHOPHYSIOLOGY IN
REFLUX NEPHROPATHY
The mechanisms for the development of ESRD in VUR are
complex. In animals, when the ﬂow of urine is obstructed
in the developing kidney a series of abnormalities occur
including (1) arrest of glomerular maturation, (2) glomeru-
losclerosis, (3) ischemia and necrosis of some tubular cells,
(4) apoptosis of other tubular and collecting duct cells,
(5) interstitial inﬂammation, proliferation, and ﬁbrosis, and
(6) tubular dilatation and atrophy [4–6]. In addition, in
animals and humans there is evidence that scarring occurs
in compound papillae where intrarenal reﬂux is present
[7]. In humans, RN is usually identiﬁed as renal scarring
as deﬁned on dimercaptosuccinic acid (DMSA) scan in a
patient known to have VUR. It is important to note that
the causality is not completely clear as some patients have
renal scarring by DMSA scan but do not have VUR. It is
also clear that pyelonephritis in the presence of VUR may
leadtonew scarring onDMSAscans;however,somepatients
with VUR have RN with renal scarring by DMSA scan at the
time of diagnosis whether or not they have had a urinary
tract infection. This is highlighted by the fact that some
patients diagnosed at birth have renal scarring as deﬁned
by DMSA scan [8, 9]. One possible explanation for this is
that damage to the kidney may occur embryonically due to
VUR. Alternatively, some of the genes that control normal
development of the ureters and ureterovesicular junction
alsocontrolrenaldevelopment.ThusVURmaybeassociated2 Advances in Urology
with either macroscopically abnormal renal development or
subtle developmental changes that predispose the kidney
to developing scarring as identiﬁed by DMSA scan. A
portion of the patients who develop ESRD related to RN
may have abnormally developed kidneys that progressively
worsen over time with further decrease in renal function
exacerbated by proteinuria, hypertension, and episodes of
pyelonephritis.Thisishighlightedbythefactthatinmultiple
studies, correction of VUR does not completely prevent the
formation of new scars [10, 11], indicating that there may
be worsening renal pathology even once VUR has been
corrected in some patients.
3. REFLUX NEPHROPATHY IS A MAJOR
CAUSE OF ESRD IN CHILDREN
Multiple registries in the United States and internationally
have identiﬁed RN as an important cause of ESRD. For
adults, RN is not a very common cause of ESRD in children.
In the USRDS database, RN is not speciﬁcally listed as
an etiology for ESRD; however, obstructive uropathy not
due to ureteropelvic junction or ureterovesicular junction
obstruction is one of the less common causes for ESRD. For
allages,obstructiveuropathyaccountedfor0.6%ofthepoint
prevalent cases for 2005 [3]; whereas diabetes accounted for
36%. The incidence of obstructive uropathy in the USRDS
has been stable at approximately 0.3% since 1994 [12], but
has increased from 0.1% for all ages for 1989–93 [13]t o
0.3% for the time periods 1994–98 [12], and 1999–2003 [3].
In the north American pediatric population, RN is reported
as the 4th leading cause for dialysis and transplantation
with 5.3% of transplant patients having a diagnosis of RN
and 3.5% of dialysis patients having a diagnosis of RN
[14]. The incidence of RN in the pediatric population has
remained stable from 2003 to 2007 [14, 15]. It is important
to note that the 2nd and 3rd leading causes for dialysis
and transplantation in children are obstructive uropathy
and aplasia/hypoplasia/dysplasia either of which can be
intertwined with RN [14]. Furthermore, in this pediatric
population another 2.6% of the transplant patients and 2%
of dialysis patients carry a diagnosis of prune belly syndrome
which is a disease of urinary obstruction in uteroand is often
associated with VUR [14]. The accuracy of these registries is
dependent on those entering data and diagnostic codes and
thus may overrepresent or underrepresent the importance of
RNinESRD.However,invariousinternationalreportsreﬂux
nephropathy either alone or in combination with congenital
obstructive disease also is identiﬁed consistently as a leading
c a u s eo fE S R D[ 16–21].
4. VUR IS COMMON IN CHILDREN; HOWEVER,
ESRD RELATED TO VUR IS RARE
In the North American Pediatric Renal Trials and Collabo-
rative Studies registry, RN accounts for approximately 5%
of the pediatric ESRD population [14]. It is possible to
dispute the accuracy of this ﬁgure as this registry depends
on voluntary reporting of data and there is no veriﬁcation of
the accuracy of the assigned diagnoses. However, if one uses
this ﬁgure as an estimate and combines it with the annual
incidence of ESRD for ages 0–18 reported by the USRDS
of 14.8 per million, then the incidence of ESRD related to
RN in the pediatric population would be approximately 0.7
per million patients [3, 14]. If one compares this annual
incidence to the estimated prevalence of VUR in the general
population, which has been recently reported as 17.2% or
172000 per million, it is clear that the vast majority of
patients with VUR do not develop ESRD. Even if one uses
older estimates of the prevalence of VUR in the general
population of 1-2% or 10000 to 20000 per million patients
[2, 22], VUR is much more common than ESRD. Since the
most common type of VUR is low-grade VUR or grades I–
III VUR, this implies that lower grade reﬂux very rarely is
associated with decreased renal function. Given that most
patientswithVURdonotdevelopESRDorevenCKD,much
work has centered on identifying those patients with VUR
who are at risk of developing CKD and ESRD. This work
has been complicated by the fact that many older reports
on outcomes of VUR were based on datasets from referral
centers, not the general pediatric population, and thus are
likely to have a strong bias towards patients with more severe
disease.
5. RISK FACTORS FOR PROGRESSION TO CKD AND
ESRD IN PEDIATRIC PATIENTS WITH VUR
Multiple retrospective trials have identiﬁed factors predictive
of progression to CKD and ESRD in pediatric patients with
VUR (Table 1).
There have been few papers that have focused solely on
progression to ESRD as a primary endpoint in patients with
RN, since, as described above, ESRD in generalis a rare event
for patients with VUR. Table 1 lists studies describing risk
factors for CKD and ESRD in patients with VUR. Ardissino
et al. retrospectively evaluated the risk of progressing from
CKD to ESRD in a cohort of 322 pediatric patients with
VURandcreatinineclearance(CrCl)<1.25mL/sper1.73m2
b o d ys u r f a c ea r e aa n df o u n da no v e r a l lr i s ko f5 6 %f o r
progressing to ESRD by the age of 20 [21]. Not surprisingly,
those patients with CrCl <0.67mL/s per 1.73m2 had a 4-
fold increased risk of progressing to ESRD compared to
those with CrCl ≥ to 0.67mL/s per 1.73m2. In addition,
age at diagnosis was not associated with an increased risk
of progression to ESRD with those diagnosed at age greater
than 6 months having no signiﬁcant diﬀerence in risk of
progression to ESRD compared to those diagnosed at age
≤6 months. In this cohort, grade IV reﬂux was the most
common grade of VUR; however, information on the grade
of VUR was reported for only 51% of the patients, making
it diﬃcult to relate risk of progression to grade of reﬂux.
29.1% of the patients were either hypertensive or being
treatedwithantihypertensive medication, demonstrating the
association between hypertension and RN. In addition, 104
of the 322 patients were evaluated for proteinuria, and
approximately 1/3 (34/104) had moderate to severe pro-
teinuria (uPr/uCr 0.95–7.2). Those patients with moderate
to severe proteinuria showed a statistically signiﬁcant larger
mean rate of CrCl decrease when compared to those withPaul Brakeman 3
Table 1: Characteristics of studies reporting CKD and ESRD data for VUR.
Study N (males)
Mean length
of F/U in
years (range)
% with reﬂux
>/= grade 3
Incidence of CKD
(upper limit of
GFR for CKD in
mL/s per 1.73m2 )
Incidence
of ESRD Predictors of ESRD/CKD
Ardissino, J
Urol, 2004 [21] 322 (245) >5 95%
N/A—CKD was an
inclusion
requirement
56% Proteinuria, CrCl
<0.67mL/s/1.73m2
Caione, BJU Int,
2004 [23] 50 (42) 6.3 (1–16) 100% 54% (1.3) 0% Creatinine r >53umol/L
in the ﬁrst year
Neild, BMC
Neph, 2004 [24] 44 (22) NR Not reported
(NR)
N/A—CKD was an
inclusion
requirement
N/A Proteinuria, GFR < CrCl
<0.83mL/s/1.73m2
Lahdes-Vasama,
NDT, 2006 [25] 267 (58) 37 (27–48) NR 67% (1.5) 9% Bilateral scarring
Mor, BJU Int,
2003 [26] 100 (21) 20–30 NR 1% (1.5) 0 NR
Silva, Ped Neph,
2006 [27] 735 (208) 6.3 (0.5–34) 60% of renal
units 3.1% (<1.25) 1.5% Hypertension
Silva, Ped Neph,
2006 [28] 184 (69) 6.5 (1.1–34) 100% 15% 5.4%
Bilateral VUR, grade V
VUR, diagnosis before
1990, diagnosis at age
>24 months
mild or no proteinuria, thus demonstrating that proteinuria
is associated with ongoing renal deterioration and may be a
target for therapies to prevent progression to ESRD.
Because having CKD increases the risk of progressing
to ESRD in patients with VUR, risk factors for progressing
to CKD are highly likely to be signiﬁcant predictors for
the progression to ESRD. Several studies have focused on
risk factors for developing CKD in patients with VUR. Silva
published data on a retrospective cohort of 735 pediatric
patients with VUR of all grades with 29% of the patients
having high-grade VUR (grades IV and V) [27]. Thus, this
cohortexhibitedsomeselectionbiasastherateofhigh-grade
VUR was signiﬁcantly higher than reported in studies in the
general population. In this cohort, 3% developed CKD (as
deﬁned by GFR <1.25mL/s per 1.73m2 body surface area
as estimated by the Schwarz formula) and 1.5% developed
ESRD (GFR <0.25mL/s per 1.73m2). Progression to CKD
was strongly associated with hypertension. As part of the
same work, Silva et al. evaluated 184 pediatric patients with
severe bilateral reﬂux (grades III–V) followed at a single
tertiary care center [28]. Mean follow-up was 78.6 months.
All patients received daily antibiotic prophylaxis and 15%
(27/184) had surgical reimplantation. In this higher-risk
cohort, the estimated probability of developing CKD was
approximately 15% at 10 years postdiagnosis of VUR. In
multivariate analysis, age at diagnosis >24 months, VUR
grade V, and bilateral renal damage were associated with
an increased risk for CKD. Interestingly, diagnosis of VUR
after 1990 was associated with reduced risk for CKD. This
data implies that our current diagnosis and treatment of
VUR may reduce the risk of developing CKD. In addition,
the estimated risk of CKD was 0% for patients with grade
III reﬂux or a negative DMSA at the time of diagnosis.
The lack of progression to CKD in those patients with a
normal DMSA at diagnosis implies that, perhaps, it is only
those kidneys with congenital lesions or that already have
been signiﬁcantly damaged at diagnosis that are at risk for
development of signiﬁcant renal impairment.
Several other studies also have focused on high-risk
populations of VUR patients. Neild et al. evaluated a high-
riskpopulationof44patientswithbilaterallyscarredkidneys
due to primary reﬂux or bladder dysfunction and GFR
0.25–1.0mL/s per 1.73m2 based on either an eGFR using
the Jelliﬀe formulae or plasma clearance of EDTA [24].
They identiﬁed a watershed GFR of 0.83mL/s per 1.73m2
below which the likelihood of progressing to ESRD increased
substantially. In addition, they identiﬁed proteinuria as
predictive of increased risk of CKD and were able to
demonstrate a protective eﬀect of ACE inhibitors on the
rate of decline of renal function for patients with eGFR
> 0.75–0.83mL/s per 1.73m2. Caione et al. retrospectively
reviewed50patientsfromItalywithbilateralVURgradesIII-
V diagnosed in the ﬁrst year of life with an average follow-
up of 6.3 years [23]. In their cohort, 54% of the patients
developed CKD as deﬁned by eGFR <1.3mL/s per 1.73m2.
All were boys, and in multivariate analysis neither number of
UTIs nor prenatal diagnosis modiﬁed the likelihood of CKD.
In multivariate analysis, a serum creatinine >53umol/L
signiﬁcantly increased the likelihood of developing CKD.
These two studies, while both small, appear to demonstrate
that there is a threshold after which renal function declines
with much greater frequency to CKD. In addition, Caione’s
study did not identify an association of CKD with febrile
UTIs,implying onceagainthat,perhaps,patientswithsevere4 Advances in Urology
VUR progress to CKD due to ongoing inﬂammation and
pathologic changes or developmental abnormalities rather
than acquired damage.
6. VERY LONG-TERM FOLLOW-UP OF VUR PATIENTS
There have been several other retrospective cohort studies
from a variety of populations with very long follow-up that
evaluated the long-term outcome of VUR. For these patients
with very long follow-up, treatment was initiated in some as
long as 40 years ago, and it is possible that current treatment
protocols, including more aggressive treatment of voiding
dysfunction, may yield diﬀerent outcomes than treatment
practices from 40 years ago. In addition, these cohorts from
several decades ago also appear to share a selection bias
towards patients with more severe VUR and higher rates of
scarring, perhaps because only the most severe VUR with
recurrent infections was diagnosed in the past. Also, renal
scarring was identiﬁed by intravenous pyelogram which is
not as sensitive as DMSA scans; thus, patients identiﬁed as
having renal scarring had more severe renal damage. Lahdes-
Vasama et al. evaluated a cohort of Finnish patients followed
for an average of 37 years [25]. They attempted to enroll
267 patients with VUR diagnosed between 1955 and 1965
but only were able to report information on current renal
function for 127 of the patients. In this cohort, 12/265 had
died due to kidney-related conditions, 7/265 had undergone
renal transplantation, and 1/265 was on hemodialysis. For
those who agreed to enroll, 85/127 had GFR <1.5mL/s per
1.73m2,4/127hadGFR<60mL/min/1.73m2,and1/127had
GFR <0.50mL/s per 1.73m2 based on the Cockcroft-Gault
formula. Among the enrolled patients, 35% had unilateral
scarring and 24% had bilateral scarring by ultrasound, and
the patients with bilateral scarring were signiﬁcantly more
likely to have reduced GFR. Interestingly, this Finnish cohort
had no increased prevalence of hypertension compared to
the rest of the Finnish population. The study implies that
approximately 7% of patients with VUR progress to ESRD;
however, the study was limited because they were unable
to evaluate grades of reﬂux or the presence or treatment
of voiding dysfunction, and there was a very high rate of
renal scarring that was severe enough to be measurable by
ultrasound. These factors indicate that there may have been
signiﬁcant selection bias in this cohort.
El-Khatib et al. reported data from 293 patients who
were diagnosed with RN or VUR between 1971 and 1986
in Australia [29]. In this group, most patients were females
who presented with febrile UTI; there was no information
on VUR grade; and 89% of the patients had renal scarring
onIVP.Thus,thispopulationwashighlyselectedforpatients
with more severe RN than a general population of patients
with VUR. In this cohort, 37% demonstrated deterioration
in renal function based on rising serum creatinine. In
multiple regression analysis, the independent risk factors
for rise in serum creatinine were proteinuria, hypertension,
elevated creatinine at presentation, bilateral VUR, and male
sex.ZhangandBaileypresentedretrospectivedataon294(59
males) patients over 15 years of age who had been followed
onaverageformorethan10years.Atlastfollow-up,24%had
creatinine clearance <1.2mL/s per 1.73m2 [30].
There have been several other smaller long-term follow-
up studies published. Mor et al. reported data from 100
Israelis (79 women and 21 men) followed for more than
20 years post antireﬂux surgery [26]. In their cohort, only
1/100 patients had an abnormal serum creatinine level;
however, eGFR was not reported, no information on voiding
dysfunction was reported and there was no information on
VUR grade. Given these limitations, this study indicates a
low risk of progression to ESRD for their cohort. Arze et
al. presented data from 130 patients (16 male) identiﬁed
in 1976 as having renal scarring as deﬁned by IVP or
pathologic evaluation of renal tissue post nephrectomy [31].
In their cohort which was followed for up to 240 months,
18% had, or developed, CKD as deﬁned by Cr >130uM/L.
Hypertension,proteinuria,andrepeatedUTIwereassociated
with increased GFR. Nakashima et al. followed 95 patients
whohadrenalscarorgradeIIIorhigherVURandfoundthat
3/995 developed ESRD and that 35% demonstrated renal
function deterioration [32]. In their cohort, bilateral scar-
ring, proteinuria >300mg per day, diastolic hypertension,
and low GFR (mean 0.82mL/s per 1.73m2) were associated
with increased risk of deterioration of renal function.
7. PREVENTION OF ESRD IN PATIENTS WITH VUR
Currently, there is little evidence from prospective, random-
ized controlled trials to direct therapies to prevent ESRD in
patients with VUR. One goal of treatment is to try to prevent
recurrent episodes of pyelonephritis and renal scarring by
treating voiding dysfunction, surgically correcting VUR,
using daily antibiotic prophylaxis and treating episodes of
pyelonephritis quickly and eﬀectively [33] (see Figure 1).
All patients should be completely evaluated and treated for
voiding dysfunction as part of the evaluation and treatment
of VUR in order to maximize bladder function and preserve
renal function. Randomized controlled trials that have tested
the beneﬁt of surgical correction of VUR or prophylactic
antibiotic treatment have not demonstrated either is more
eﬃcacious in preventing renal scarring or the overall rate
of recurrent UTIs [10, 11]. Critically, these studies did not
haveacontrolgroupthatreceivedonlyobservation.Inoneof
these trials, the International Reﬂux Study in Children trial,
surgical correction of grades III and IV reﬂux did reduce
the occurrence of febrile UTI. Unfortunately, this did not
correspond to a decrease in new renal scars or an improve-
ment in renal function in surgically treated children [10].
Several recent reports have questioned the utility of daily
antibiotic prophylaxis [34–36]; however, it is important to
note that the studies from Garin et al. [35]a n d[ 34]C o n w a y
et al. reported on few male subjects and did not address
high-grade VUR. Speciﬁcally, the Garin trial excluded those
with VUR grades IV and V, and the Conway study included
only 10 patients with VUR grades IV and V. Another
recent randomized prospective trial demonstrated a beneﬁt
of prophylactic antibiotics versus observation in preventing
positive surveillance urine cultures in asymptomatic boys
withgradeIIIVUR[37].Inthenearfuture,wewillhopefullyPaul Brakeman 5
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Figure 1: Schematic representation of factors involved in progres-
sion to ESRD for patients with VUR. In the majority of patients
with VUR, VUR resolves and the patients demonstrate normal
renal function (green pathway). Some patients with renal scarring
and/or who have recurrent pyelonephritis also retain normal
renal function (green arrows). Other patients with VUR develop
RN, proteinuria, and hypertension. In all cases, abnormal renal
development can accompany RN and contribute to renal scarring,
proteinuria, hypertension, and progression to CKD (solid black
arrows). Prevention of ESRD focuses on intervening to prevent
recurrent pyelonephritis (1), by actively evaluating and treating
episodes of pyelonephritis to prevent renal scarring (2), and by
treating hypertension (3) and proteinuria (4) to preserve renal
function.
havenewdatafromalarge,multicentertrialcomparingdaily
antibiotic prophylaxis versus observation in patients with
low-grade reﬂux [38]. At this point in time, there does not
appear to be good evidence to support using daily antibiotic
prophylaxis to prevent UTI or renal scarring in patients with
VUR grades I–III; nor is there evidence that for grades III-IV
VUR surgical correction of VUR prevents new renal scarring
compared to daily antibiotic prophylaxis. Because grade V
VUR is rare, there have not been any signiﬁcant randomized,
controlled, prospective trials to evaluate treatment options.
Thus,thetreatmentsthatmaypreventESRDinthishigh-risk
population are incompletely characterized. For patients with
highriskofprogressiontoCKDandESRDsuchasthosewith
grade IV and V reﬂux, signiﬁcant renal scarring and those
with reduced GFR, the surgical correction of reﬂux and daily
antibiotic prophylaxis should be strongly considered; and
risks and beneﬁts of these treatments should be discussed
with families. In addition, close clinical follow-up and rapid
treatment of episodes of pyelonephritis should be instituted
to preserve renal function and prevent progression to ESRD.
8. HYPERTENSION AND PROTEINURIA AS
THERAPEUTIC TARGETS FOR PREVENTION
OF ESRD
Another aspect of preventing the progression of RN to ESRD
is the treatment of hypertension and proteinuria, both of
whichareindicatorsofrenaldamageandcontributetoongo-
ing deterioration of renal function in many renal conditions.
As described above, multiple studies have demonstrated a
correlation between RN and hypertension. Hypertension has
been shown to aﬀect the rate of decline of renal function in
other conditions, thus controlling hypertension should be a
signiﬁcant goal for treatment of patients with VUR.
In addition, multiple studies have demonstrated a cor-
relation between proteinuria and risk for CKD in RN. The
magnitude of proteinuria associated with increased risk of
CKD or deterioration of function varies somewhat but even
mild proteinuria appears to be associated with increased risk
for renal deterioration. El-Khatib et al. showed an increased
risk of deterioration of renal function for patients with
>0.2G per day of proteinuria with a progressively increasing
risk of deterioration for patients with >1Gperdayofpro-
teinuria [29]. Nakashima et al. demonstrated an increased
risk for deterioration of renal function for patients with
>0.3G/dayofproteinuria[32].Neildetal.alsodemonstrated
a correlation between increased proteinuria and elevated
creatinine with patients having a GFR of 0.25mL/s per
1.73m2 to 0.5mL/s per 1.73m2 having an average protein to
creatinine ratio of 209mg/mmol compared to 38mg/mmol
for those patients with GFR of 0.83mL/s per 1.73m2 to
1.0mL/s per 1.73m2[24].
Neild et al. also presented the only data in VUR patients
that ACE inhibitors may be able to slow the progression
of renal deterioration associated with severe RN [24]. One
caveat to their ﬁnding was that beneﬁt of ACE inhibition was
demonstrated only for those patients with mildly reduced
GFR of 0.83mL/s per 1.73m2 to 1.0mL/s per 1.73m2 [24].
There is evidence that in nondiabetic patients with renal
parenchymal abnormalities that ACE inhibition reduces
proteinuria and may help to preserve renal function [39–
41]. Given the beneﬁt of ACE inhibition in other renal
conditions and the limited, but promising, data presented by
Neild et al. [24], ACE inhibitors and/or angiotensin receptor
blocking agents should be the ﬁrst choice for controlling
hypertensionandproteinuriaandshouldbeinitiatedearlyin
the course of disease. Furthermore, based on data from other
nondiabetic renal disease, one should use ACE inhibition
and/or angiotensin receptor blockade even in the absence
of hypertension when a patient has VUR and proteinuria.
Controlling hypertension and proteinuria in patients with
VURshouldbeconsideredstandardmaintenancetherapyfor
those with VUR and RN.
9. CONCLUSIONS
VUR is commonly identiﬁed in pediatric patients and can
be associated with reﬂux nephropathy, CKD, and, rarely,
ESRD. The progression of RN to CKD and ESRD is more
likely in patients with reduced GFR, bilateral VUR and/or
renal scarring, grade V VUR, proteinuria, and hypertension.
Identiﬁcation of patients with these clinical characteristics
should be the goal of clinical, biochemical, and radiological
to evaluation of patients presenting with hydronephrosis
on prenatal ultrasound or febrile UTI. Because progression
to ESRD is rare in VUR and often requires many decades
to develop, there are limited prospective, randomized, con-
trolled trials available to direct therapy. All patients should6 Advances in Urology
be evaluated and treated for voiding dysfunction, where
appropriate, and rapidly diagnosed and treated for recurrent
pyelonephritis. Evaluation and treatment of patients with
VUR should be directed at preventing pyelonephritis and
new renal injury; however, there is little evidence that either
surgicalcorrectionofVURorantibioticprophylaxisprevents
pyelonephritis and new renal scarring in comparison to
careful clinical observation alone. In addition, for those
patients who do develop RN, care should be taken to
normalize blood pressure and reduce proteinuria in order to
preserve renal function. In the future, with continued basic
research,wemaybeabletodeveloppharmaceuticaltherapies
aimed directly at the molecular pathophysiology of RN to
slow progression of RN to ESRD. For now, we must provide
thebestsupportivecaretopatientstopreserverenalfunction
and prevent ESRD in patients with vesicoureteral reﬂux and
reﬂux nephropathy.
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